RotaTeq® is designed to contain the five serotypes that account for the majority of rotavirus infections worldwide. The vaccine provides high and consistent efficacy against these common circulating serotypes. Its development required novel solutions for manufacturing, testing, and formulation for each of the reassortants. In one of the largest vaccine clinical trials ever conducted, RotaTeq® was well tolerated, with High efficacy demonstrated against serious rotavirus disease.
